+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peripherally Acting Anti-Obesity Drug Market - Global Forecast 2025-2030- Product Image
Peripherally Acting Anti-Obesity Drug Market - Global Forecast 2025-2030- Product Image
Sale

Peripherally Acting Anti-Obesity Drug Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6139323
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior healthcare decision-makers are actively seeking data-driven strategies to address rising obesity rates and associated comorbidities. Peripherally acting anti-obesity treatments are now positioned at the intersection of regulatory shifts, patient-centric delivery, and global supply chain trends, restructuring therapeutic and commercial approaches. This report analyzes the peripherally acting anti-obesity drug market, focusing on current drivers, challenges, and competitive opportunities in a rapidly evolving environment.

Market Snapshot: Peripherally Acting Anti-Obesity Drug Market

The global peripherally acting anti-obesity therapeutics market is experiencing dynamic expansion, supported by product innovation, integration of digital health, and changes in reimbursement models. Growing prevalence of obesity, combined with regulatory support for advanced treatments and the emergence of remote patient management technologies, is fueling market growth. Stakeholders recognize the opportunity to improve patient outcomes through therapies that reduce cardiovascular risks, enhance safety and tolerability, and deliver sustainable weight management solutions across multiple regions and healthcare settings.

Scope & Segmentation of the Peripherally Acting Anti-Obesity Drug Market

This report offers detailed segmentation and regional analysis, enabling targeted strategies for a diverse market landscape.

  • Product Types: GLP-1 receptor agonists (long-acting—monthly or weekly injections, short-acting), lipase inhibitors
  • Route of Administration: Injectable, oral
  • Distribution Channels: OTC, prescription
  • Dosage Forms: Capsule, suspension, tablet
  • End Users: Clinics, home care, hospitals
  • Treatment Indications: Class I and II obesity, Class III obesity
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (multiple country markets), and Asia-Pacific (major countries including China, India, Japan, Australia, and more)
  • Leading Companies: F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Viatris Inc., Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Cipla Ltd, Lupin Limited, Aurobindo Pharma Limited

Technological integration, digital health collaborations, and supply chain advancements are emphasized to address region- and segment-specific treatment needs.

Key Takeaways for Senior Decision-Makers

  • Pharmacological advances in the peripherally acting anti-obesity drug landscape minimize central nervous system exposure, improving safety profiles and tolerability for broader patient adoption.
  • The therapeutic market is reshaped by emerging reimbursement models that tie outcome-driven results to pricing, driving alignment among payers, manufacturers, and health providers.
  • Collaborations between pharmaceutical firms, digital health innovators, and academic centers foster integrated obesity management platforms, supporting remote adherence monitoring and tailored patient interventions.
  • Segmentation insights reveal shifting end-user demands and regional nuances, compelling stakeholders to adapt strategies for localized treatment protocols and differentiated access paths.
  • Patient advocacy influences trial design and post-market surveillance, accelerating quality-of-life initiatives and amplifying access priorities in key territories.
  • Investment in advanced domestic manufacturing reflects industry response to anticipated trade volatility and regulatory unpredictability in key markets.

Tariff Impact on Global and US Peripherally Acting Anti-Obesity Drug Markets

The introduction of United States trade tariffs in 2025 is forecasted to increase input costs for manufacturers relying on imported active pharmaceutical ingredients. This policy shift prompts industry recalibration toward nearshoring supply and dual sourcing to ensure operational continuity. Strategic manufacturing investments now focus on localized production, granting greater quality control and resilience against supply chain disruptions. Tariff-related cost pressures may alter pricing negotiations and formulary access decisions, encouraging agile scenario planning for both tender participation and long-term supplier engagement.

Methodology & Data Sources

This report’s findings are grounded in a multi-tiered methodology: structured interviews with clinical and policy experts, robust secondary research from regulatory and proprietary registries, and advanced quantitative and qualitative analysis. Rigorous cross-validation maintains consistency and reliability, while scenario modeling accounts for policy, reimbursement, and competitive changes. All insights are validated through iterative review processes for strategic accuracy.

Why This Report Matters

  • Facilitates evidence-based investment and portfolio management decisions by mapping technology, regulatory, and patient engagement trends.
  • Enables stakeholders to anticipate commercial and operational risks tied to shifting trade landscapes, reimbursement evolution, and competitive repositioning.
  • Equips leaders with actionable analysis of product, channel, and geographic segmentation to inform resource allocation and market entry or expansion strategies.

Conclusion

Peripherally acting anti-obesity drugs are at the forefront of innovation, policy adaptation, and multidisciplinary care transformation. Informed actions based on comprehensive market intelligence position stakeholders to advance patient outcomes and meet evolving healthcare expectations globally.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing adoption of combination therapies with peripheral receptor modulators to enhance weight loss efficacy
5.2. Technological advancements in nanoformulation for targeted peripheral anti-obesity drug delivery
5.3. Rising investment in oral peptide stabilization techniques for peripherally acting obesity drugs
5.4. Expansion of global partnerships to accelerate peripheral anti-obesity drug clinical development
5.5. Shifts in regulatory guidelines to fast-track approval of novel peripheral obesity therapeutics
5.6. Increasing patient preference for non-invasive peripheral anti-obesity treatments with minimal side effects
5.7. Emergence of real-world evidence in demonstrating long-term safety of peripheral obesity pharmacotherapies
5.8. Innovations in biomarkers for predicting patient response to peripherally acting anti-obesity drugs
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Peripherally Acting Anti-Obesity Drug Market, by Product Type
8.1. Introduction
8.2. Glp-1 Receptor Agonist
8.2.1. Long Acting
8.2.1.1. Monthly Injection
8.2.1.2. Weekly Injection
8.2.2. Short Acting
8.3. Lipase Inhibitor
9. Peripherally Acting Anti-Obesity Drug Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
10. Peripherally Acting Anti-Obesity Drug Market, by Distribution Channel
10.1. Introduction
10.2. Otc
10.3. Prescription
11. Peripherally Acting Anti-Obesity Drug Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.3. Suspension
11.4. Tablet
12. Peripherally Acting Anti-Obesity Drug Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Peripherally Acting Anti-Obesity Drug Market, by Treatment Indication
13.1. Introduction
13.2. Class I And Ii Obesity
13.3. Class Iii Obesity
14. Americas Peripherally Acting Anti-Obesity Drug Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Peripherally Acting Anti-Obesity Drug Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd
17.3.2. GlaxoSmithKline plc
17.3.3. Teva Pharmaceutical Industries Ltd
17.3.4. Sandoz International GmbH
17.3.5. Viatris Inc.
17.3.6. Sun Pharmaceutical Industries Ltd
17.3.7. Dr. Reddy’s Laboratories Ltd
17.3.8. Cipla Ltd
17.3.9. Lupin Limited
17.3.10. Aurobindo Pharma Limited
18. Research AI19. Research Statistics20. Research Contacts21. Research Articles22. Appendix
List of Figures
FIGURE 1. PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET: RESEARCHAI
FIGURE 28. PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET: RESEARCHSTATISTICS
FIGURE 29. PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET: RESEARCHCONTACTS
FIGURE 30. PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY MONTHLY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY MONTHLY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY WEEKLY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY WEEKLY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY SHORT ACTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY SHORT ACTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LIPASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LIPASE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY OTC, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY OTC, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY CLASS I AND II OBESITY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY CLASS I AND II OBESITY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY CLASS III OBESITY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY CLASS III OBESITY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 97. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 98. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 99. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 100. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 101. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 102. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 103. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 108. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 109. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 112. CANADA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 113. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 116. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 117. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 118. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 119. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 124. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 125. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 195. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 196. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 197. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 198. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 199. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 200. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 201. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 206. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 207. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 210. GERMANY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 211. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 214. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 215. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 216. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 217. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 222. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 223. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 226. FRANCE PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 243. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 246. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 247. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 248. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 249. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 254. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 255. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 258. ITALY PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 259. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 260. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 261. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 262. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 263. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 264. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 265. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 270. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 271. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2018-2024 (USD MILLION)
TABLE 274. SPAIN PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY TREATMENT INDICATION, 2025-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY GLP-1 RECEPTOR AGONIST, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY LONG ACTING, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES PERIPHE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Peripherally Acting Anti-Obesity Drug Market report include:
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Cipla Ltd
  • Lupin Limited
  • Aurobindo Pharma Limited

Related Topics

Related Reports

Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players - Product Image

Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players

  • Report
  • 240 Pages
  • Global
From
North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029 - Product Image

North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029

  • Report
  • 72 Pages
  • North America
From
Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032 - Product Image

Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Asia Pacific
From
Anti-Obesity Drugs Market - Global Forecast 2025-2030 - Product Image

Anti-Obesity Drugs Market - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Anti-Obesity Drugs Market Report and Forecast 2025-2034 - Product Image

Anti-Obesity Drugs Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.